Sentences with phrase «patient cell model»

Not exact matches

«In theory, we could model progression of the disease by reprogramming skin cells from patients at a range of ages, including before symptoms begin.

To develop their «disease in a dish» model, the team took skin cells from patients with Allan - Herndon - Dudley syndrome and reprogrammed them into induced pluripotent stem cells, which then can be developed into any type of tissue in the body.

Using these cells, the team modeled the patients» neurons and blood - brain barrier in a laboratory dish.

They also determined that blocking the enzyme reduces multiple myeloma regeneration in experimental models derived from patient cancer cells.

«This research has broad impact, because by deepening our understanding of cell reprogramming we have the potential to improve disease modeling and the generation of better sources of patient - specific specialized cells suitable for replacement therapy,» said Plath.

In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvania.

Guo and his collaborators continue their studies by establishing additional mouse models of leukemia that have been transplanted with patient cells of relapsed and refractory disease.

We were able to show that progenitor cells in our model and in patients with essential thrombocythemia, had a signature of excessive thrombopoietin stimulation.

The research is also the first to demonstrate beneficial effects of UDCA on dopaminergic neurons, the nerve cells affected in Parkinson's disease, in a fly model of Parkinson's disease which carries the same genetic change as some patients with the condition.

Realistic stem cell therapies to replace diseased or damaged tissue may still be years away, but researchers have uncovered a promising new use for these undifferentiated cells: they can be programmed to become patient - specific laboratory models of inherited liver disease.

These techniques include: human tissue created by reprogramming cells from people with the relevant disease (dubbed «patient in a dish»); «body on a chip» devices, where human tissue samples on a silicon chip are linked by a circulating blood substitute; many computer modelling approaches, such as virtual organs, virtual patients and virtual clinical trials; and microdosing studies, where tiny doses of drugs given to volunteers allow scientists to study their metabolism in humans, safely and with unsurpassed accuracy.

«With this breakthrough it is possible to generate cell models with the same alterations as observed in tumour cells from patients, which will allow us to study their role in tumour development,» says CNIO researcher Sandra Rodríguez - Perales.

Currently, Deng's laboratory is conducting additional preclinical studies using the human - derived stem cells from Down syndrome patients and mouse models to determine whether cellular and behavioral abnormalities can be improved with minocycline therapy and other candidate drugs.

In addition to looking at mouse models of diabetes, the researchers also showed that exposure of human pancreatic islet cells — both from healthy donors and from patients with Type 1 diabetes — to fasting - mimicking diet in a dish stimulated insulin production.

In addition to helping understand disease by providing more powerful study models, «what this technology would allow you to do is reprogram a skin cell, for example, from a Parkinson's patient... into a pluripotent cell and then in a petri dish redirect that cell into... a neuron» to treat that patient.

«This model is more realistic than traditional animal models because it is derived from a patient's own cells.»

This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.

Induced pluripotent stem cells (iPSCs)-- adult cells reprogrammed back to an embryonic stem cell - like state — may better model the genetic contributions to each patient's particular disease.

«Most previous research into ways of delaying the onset of HD symptoms have focused on studying the mutant protein in cells or in animal models, but the relevance of abnormalities in those systems to what actually happens in patients remains a huge assumption,» says James Gusella, PhD, director of the Center for Human Genetic Research (CHGR) at Massachusetts General Hospital (MGH), corresponding author of the Cell paper.

However, he added, the patient - derived iPSCs are highly useful as a model cell system for investigating blood disorders.

In particular, although radiation treatment regimens for some other cancers have been found to unleash an anti-tumor response by the patient's own T - cells, the team found no such effect in their pancreatic cancer model.

To develop a more accurate method, Higgins and colleagues designed a mathematical model of glucose chemistry and red blood cell turnover and combined it with large data sets of patient glucose measurements.

By taking the age of patients» blood cells into account, the researchers» model, when tested in more than 200 diabetic patients, reduced the error rate from one in three patients with the standard blood test to an error rate of one in 10.

Furthermore, the cells offer a renewable, long - lasting model system for testing drug candidates or gene modifications that may offer new treatments, personalized to individual patients.

Desgrosellier said the team will follow up with mouse models containing tumor fragments from patients to better reflect the diversity of cell types present in human disease.

Dr Leonardo Guasti added: «It represents an entirely new concept for the study of the adrenal gland as the ability to generate donor - specific and functional adrenal - like cells will facilitate the next generation of cell - based treatments for adrenal insufficiency, the modelling of adrenal specific diseases, and the testing of personalised interventions on cells derived from patients.»

The disease model, described in a new study by a UC San Francisco - led team, involves taking skin cells from patients with the bone disease, reprogramming them in a lab dish to their embryonic state, and deriving stem cells from them.

But he also has a team working on the model that occurred to him on the beach: Harvest and grow some healthy cells from a patient's damaged kidneys.

A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer.

EZH2 inhibition delayed tumor onset in KDM6A - null cells and caused regression of KDM6A - null bladder tumors in both patient - derived and cell line xenograft models.

«This model supported cancer development so strongly that some mice developed invasive squamous cell skin cancers similar to the patient's tumor,» said lead author Shadmehr Demehri, MD, PhD, a dermatologist and postdoctoral fellow.

To conduct their study, Kaur, Baiocchi and their colleagues used tumor tissue from patients, cell lines and an animal model.

Until now, little was known in preclinical models about the mechanisms that allow breast cancer cells to leave the latent state and even less is known in patients,» explains Roger Gomis, head of the Growth Control and Cancer Metastasis Lab.

Studies of IBD are typically performed using cell culture experiments or animal models, which don't mimic the precise conditions that occur in the gut of human patients.

«The new model enables studies of the complex interactions between host cells, mucus production, and gut microbes in a system that closely mimics the situation in human patients,» Dawson said.

Using a combination of cell - based and mouse models, the researchers showed that the recently - evolved mycobacteria were more virulent, likely to cause more serious disease in patients.

«Alzheimer's in a dish: Stem cells from patients offer model and drug - discovery platform for early onset form of disease.»

Importantly, these devices also will open up new approaches to drug development not possible with animal models today, such as personalized medicines and development of therapeutics for specific genetic subpopulations using chips created using cells from particular patients.»

«Urine - derived stem cells predict patient response to cholesterol - lowering drugs: Urine - derived iPSCs model hypercholesterolemia.»

Reported today in Disease Models & Mechanisms, Karim Si - Tayeb and colleagues in the research group of Bertrand Cariou from l'Institut du Thorax, Nantes used an innovative approach to develop unique patient cell - based models of PCSK9 - driven hypercholesteroModels & Mechanisms, Karim Si - Tayeb and colleagues in the research group of Bertrand Cariou from l'Institut du Thorax, Nantes used an innovative approach to develop unique patient cell - based models of PCSK9 - driven hypercholesteromodels of PCSK9 - driven hypercholesterolemia.

«Use of induced pluripotent stem cell (iPSC) technology» — which involves taking skin cells from patients and reprogramming them into embryonic - like stem cells capable of turning into other specific cell types relevant for studying a particular disease — «makes it possible to model dementias that affect people later in life,» says senior study author Catherine Verfaillie of KU Leuven.

Cheng, an assistant professor of medicine in hematology / oncology at Feinberg, provided the cell lines and NanoFlare targets the researchers used to model blood samples taken from breast cancer patients.

Treating the potentially blinding haze of a scar on the cornea might be as straightforward as growing stem cells from a tiny biopsy of the patient's undamaged eye and then placing them on the injury site, according to mouse model experiments conducted by researchers at the University of Pittsburgh School of Medicine.

He is also developing a robust and comprehensive panel of 3 - D cell culture models from patient - derived primary cells that can be used to characterize different disease phenotypes and investigate the chemo - response of cells to novel or known drugs.

The study, called «Molecular Determinants of Drug - Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,» and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.

In experiments with cancer cell lines, the PIM1 inhibitors killed cells in a MYC - dependent manner, and in two different mouse models — one in which mice were implanted with patient tumors and the other in which a genetic alteration of MYC predisposes the mice to tumor development — the administration of PIM1 inhibitors resulted in significant tumor regression.

Meng and Nel also collaborated with Dr. Timothy Donahue, chief of gastrointestinal and pancreatic surgery and a Jonsson Comprehensive Cancer Center member, to demonstrate that treatment with the iRGD peptide can enhance tumor cell killing for patient - derived pancreatic cancers, growing subcutaneously in a mouse model.

In patient - derived animal models, they found that just three doses of the compound, called 17S - FD - 895, significantly reduced the ability of leukemia stem cells to self - renew.

The ultimate goal is to use stem cells of an individual patient and create a personalized model of their reproductive system.

Ultimately, the goal is to use stem cells of an individual patient and create a personalized model of their reproductive system to test new drugs for safety and effectiveness.